The latest in MOFCOM's remedy supervision

O'Melveny & Myers

5 minute readNovember 26, 2015 at 01:48 AM
By
Katherine Jo

Nate Bush and Lining Shan [email protected] and [email protected]

Many antitrust regulators worldwide prefer to address potential anti-competitive effects from mergers among competitors with one-time “structural” fixes (such as divestitures of subsidiaries, facilities or IP), wary that “behavioral” remedies that restrict merger parties' future commercial conduct may entail ongoing administrative costs and unintended harm to consumers.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

  • ✓ A database of 3000+ essential documents, including key PRC laws translated into English
  • ✓ Newsletters with business-critical and sector-specific updates
  • ✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)